By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Almost one year to the day after pulling a planned initial public offering, Seattle-based Atossa Genetics has refiled with US regulators to go public.

In a Form S-1 filed Feb. 13 with the US Securities and Exchange Commission Atossa said it seeks to sell 1 million shares of its common stock at a price of between $5 and $7 per share, raising up to a little more than $8 million.

The company plans to list on the Nasdaq Capital Market under ticker symbol "ATOS."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.